Cooperative Agreement R41CA232805

The National Cancer Institute (NCI) awarded a $647,458 Cooperative Agreement under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Massachusetts Institute of Technology (MIT) to develop a novel platform for real-time functional assessment of Acute Myeloid Leukemia (AML) minimal residual disease (MRD) therapeutic vulnerabilities. The project aims to integrate MIT's high-precision biophysical measurements, DeepCell's label-free brightfield imaging and AI-powered sorting,...

This Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $882,247 to the University of Pittsburgh to conduct a Phase 2 clinical trial evaluating the efficacy of interferon-gamma (IFN-γ) and donor lymphocyte infusion (DLI) for treating relapsed myeloid malignancies in patients who have undergone allogeneic stem cell transplantation. The trial aims to enroll 45 participants and will compare outcomes to synthetic control cohorts from the Center...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $433,895.00 to the Sloan-Kettering Institute for Cancer Research to examine the psychosocial, ethical, and clinical implications of incidental medical findings of clonal hematopoiesis (CH) in healthy hematopoietic stem cell (HSC) donors. The award will fund a feasibility study to (1) qualitatively assess the psychosocial impact of receiving information about incidental CH...

The National Cancer Institute (NCI) awarded a $678,228 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The three-phase study will optimize, verify, and validate the GLISCAN assay, which aims to quantify tumor mutations (TERT C228T/C250T,...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $2,078,214 Project Grant to Precision Epigenomics Inc., a University of Arizona Cancer Center and Department of Pathology spin-out, to develop and validate the Sentinel-MPE liquid biopsy assay - a multi-cancer detection test that can identify over twenty different cancer types. The project aims to establish the diagnostic value of the Sentinel-MPE test and validate its use for cancer detection in...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $590,960.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at improving the understanding and treatment of acute myeloid leukemia (AML). The key objectives of the project are to: 1) Quantify the dynamics of leukemia potential driven by different oncogenic signals in murine models, 2) Evaluate the effects of treatment on leukemia...

This $429,000 Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research (CFDA 93.395) federal grant program, supports research by Western University of Health Sciences to develop a novel chimeric antigen receptor (CAR) natural killer (NK) cell therapy that can specifically target acute myeloid leukemia (AML) with human leukocyte antigen (HLA)-DR loss. The goal is to create a dual CAR-NK cell that expresses an activating CAR against the AML antigen CD33 and...

This federal Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides funding of $244,000.00 to the Oregon Health & Science University (OHSU) to investigate the benefits of intensive induction chemotherapy followed by immediate hematopoietic cell transplantation (HCT) for patients with intermediate and high-risk acute myeloid leukemia (AML). The project aims to determine if this...

This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), provides $206,968 to the University of Arizona to develop and validate a gene expression assay called FL24CX. The goal is to use this assay to predict early clinical failure in patients with follicular lymphoma who are treated with immunochemotherapy. The project has two phases: (1) analytical validation of the FL24CX...

This Project Grant award, with ID R01CA292596, was provided by the National Cancer Institute (NCI) under the federal Cancer Treatment Research program (CFDA 93.395). The award totals $738,698.00 and runs from March 7, 2025 to February 28, 2030. The primary objective is to evaluate the combination of anti-CD38 targeted alpha therapy (TAT) and total marrow irradiation (TMLI) conditioning regimens for the treatment of relapsed/refractory acute myelogenous leukemia (AML) in patients over 60 years...